secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001493152-25-022310
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo Pharma Q1 net loss $2.2M; advances IV selonabant Phase 1 study
----------------------------------------------------------------------

- Net loss of $2.2M ($0.05/sh) in Q1 FY2026, flat vs prior year; operating expenses $2.3M.
- Cash $10.4M at Sept 30, 2025; plus $3M available under loan agreement.
- First subjects dosed in Phase 1 SAD study of IV selonabant for pediatric cannabis toxicity; FDA-cleared design.
- Received $994,300 second-year tranche of NIDA/NIH grant to support the SAD study.
- Board continues strategic review including proposed reverse stock split and going-private transaction; SEC comments delayed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315225022310/0001493152-25-022310-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315225022310/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-022310

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer